Expression of down stream molecules of RET (p-ERK, p-p38 MAPK, p-JNK and p-AKT) in papillary thyroid carcinomas

Yonsei Medical Journal

Volumn 45, Issue 2, 2004, Pages 306-313

  Shin, Eunah ^a   Hong, Soon Won ^a   Kim, Se Hoon ^a   Yang, Woo Ick ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

AKT; ERK; Immunohistochemistry; JNK; p38 MAPK; Papillary thyroid carcinoma; RET

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; PROTEIN RET; STRESS ACTIVATED PROTEIN KINASE; SYNAPTOPHYSIN;

ADULT; AGED; ANALYTIC METHOD; ARTICLE; CANCER SURVIVAL; CARCINOGENESIS; CELL NUCLEUS; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; STATISTICAL ANALYSIS; THYROID PAPILLARY CARCINOMA; TUMOR CELL;

EID: 2442711333     PISSN: 05135796     EISSN: None     Source Type: Journal    
DOI: 10.3349/ymj.2004.45.2.306     Document Type: Article

References (39)

1. Fusco A, Grieco M, Santoro M, Berlingieri MT, Pilotti S, Pierotti MA, et al. A new oncogene in human thyroid papillary carcinomas and their lymph-nodal metastases. Nature 1987;328:170-2.
2. Grieco M, Santoro M, Berlingieri MT, Melillo RM, Donghi R, Bongarzone I, et al. PTC is a novel rearranged form of ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas. Cell 1990;60:557-63.
3. Ishizaka Y, Shima H, Sugimura T, Nagao M. Detection of phosphorylated retTPC oncogene product in cytoplasm. Oncogene 1992:7:1441-4.
4. Bongarzone I, Butti MG, Coronelli S, Borrello MG, Santoro M, Mondellini P, et al. Frequent mutation of ret protooncogene by fusion with a new activating gene in papillary thyroid carcinomas. Cancer Res 1994;54:2979-85.
5. Jhiang SM. The RET proto-oncogene in human cancers. Oncogene 2000;190:5590-7.
6. Tallini G, Asa SL. RET oncogene activation in papillary thyroid carcinoma. Adv Anat Pathol 2002;8:345-54.
7. Sugg SL, Zheng L, Rosen IB, Freeman JL, Ezzat S, Asa SL. ret/PTC-1, -2, and -3 oncogene rearrangements in human thyroid carcinomas: implications for metastatic potential? J Clin Endocrinol Metab 1996;81:3360-5.
8. Tallini G, Santoro M, Heile M, Carlomagno F, Salvatore G, Chiappetta G, et al. RET/PTC oncogene activation defines a subset of papillary thyroid carcinomas lacking evidence of progression to poorly differentiated or undifferentiated tumor phenotypes. Clin Cancer Res 1998; 4:287-94.
9. Kjellman P, Learoyd DL, Messina M, Weber G, Hoog A, Wallin G, et al. Expression of the RET proto- oncogene in papillary thyroid carcinoma and its correlation with clinical outcome. Br J Surg 2001;88:557-63.
10. Sugg SL, Ezzat S, Rosen IB, Freeman JL, Asa SL. Distinct multiple RET/PTC gene rearrangements in multifocal papillary thyroid neoplasia. J Clin Endocrinol Metab 1998;83:4116-22.
11. Thomas GA, Bunnell H, Cook HA, Williams ED, Nerovnya A, Cherstvoy ED, et al. High prevalence of RET/PTC rearrangements in Ukrainian and Belarussian post-Chernobyl thyroid papillary carcinomas: a strong correlation between RET-PTC3 and the solid-follicular variant. J Clin Endocrinol Metab 1999;84:4232-8.
12. Cheung CC, Ezzat S, Freeman JL, Rosen IB, Asa SL. Immunohistochemical diagnosis of papillary thyroid carcinoma. Mod Pathol 2001;4:338-42.
13. Bunone G, Uggeri M, Mondellini P, Pierotti MA, Bongarzone I. RET receptor expression in thyroid follicular epithelial cell-derived tumors. Cancer Res 2000;60: 2845-9.
14. Fluge Ø, Haugen DR, Akslen LA, Marstad A, Santoro M, Fusco A, et al. Expression and alternative splicing of cRET RNA in papillary thyroid carcinomas. Oncogene 2001;20:885-92.
15. Santoro M, Melillo RM, Grieco M, Berlingieri MT, Vecchio G, Fusco A. The TRK and RET tyrosine kinase oncogenes cooperate with ras in the neoplastic transformation of a rat thyroid epithelial cell line. Cell Growth Differ 1993;4:77-84.
16. Jhiang SM, Sagartz JE, Tong Q, Parker-Thornburg J, Capen CC, Cho JY, et al. Targeted expression of the ret/PTC1 oncogene induces papillary thyroid carcinomas. Endocrinology 1996;137:375-8.
17. Santoro M, Chiappetta G, Cerrato A, Salvatore D, Zhang L, Manzo M, et al. Development of thyroid papillary carcinomas secondary to tissue-specific expression of the RET-PTC1 oncogene in transgenic mice. Oncogene 1996;12:1821-6.
18. Powell DJ Jr, Russell J, Nibuk K, Rhee E, Liao M, Goldstein M, et al. The RET-PTC3 oncogene: metastatic solid type papillary carcinomas in murine thyroids. Cancer Res 1998;58:5523-8.
19. Bond JA, Wyllie FS, Rowson J, Radulescu A, Wynford-Thomas D. In vitro reconstruction of tumor initiation in a human epithelium. Oncogene 1994;9:281-90.
20. Fischer AH, Bond JA, Taysavang P, Battles OE, Wynford-Thomas D. Papillary thyroid carcinoma oncogene (RET/PTC) alters the nuclear envelope and chromatin structure. Am J Pathol 1998;153:1443-50.
21. Carlomagno F, Vitagliano D, Guida T, Napolitano M, Vecchio G, Fusco A, et al. The kinase inhibitor PP1 blocks tumorigenesis induced by RET oncogenes. Cancer Res 2002;62:1077-82.
22. Carlomagno F, Vitagliano D, Guida T, Basolo F, Castellone MD, Melillo RM, et al. Efficient inhibition of RET/papillary thyroid carcinoma oncogenic kinases by 4-amino-5-(4-chloro-phenyl)-7-(t-butyl) pyrazolo [3,4-d] pyrimidine (PP2). J Clin Endocrinol Metab 2003;88: 1897-902.
23. Lanzi C, Cassinelli G, Cuccuru G, Zaffaroni N, Supino R, Vignati S, et al. Inactivation of Ret/Ptc1 oncoprotein and inhibition of papillary thyroid carcinoma cell proliferation by indolinone RPI-1. Cell Mol Life Sci 2003;60:1449-59.
24. Pandey A, Liu X, Dixon JE, Di Fiore PP, Dixit VM. Direct association between the Ret receptor tyrosine kinase and the Src homology 2-containing adapter protein Grb7. J Biol Chem 1996;271:10607-10.
25. Alberti L, Borrello MG, Ghizzoni S, Torriti F, Rizzetti MG, Pierotti MA. Grb2 binding to the different isoforms of Ret tyrosine kinase. Oncogene 1998;17:1079-87.
26. Borrello MG, Alberti L, Arighi E, Bongarzone I, Battistini C, Bardelli A, et al. The full oncogenic activity of Ret/ptc2 depends on tyrosine 539, a docking site for phospholipase C gamma. Mol Cell Biol 1996;16:2151-63.
27. Asai N, Murakami H, Iwashita T, Takahashi M. A mutation at tyrosine 1062 in MEN2A-Ret and MEN2B-Ret impairs their transforming activity and association with Shc adaptor proteins. J Biol Chem 1996;271:17644-9.
28. Takahashi H. The GDNF/Ret signaling pathway and human diseases. Cytokine Growth Factor Rev 2001;12: 361-73.
29. Chiariello M, Visconti R, Carlomagno F, Melillo RM, Bucci C, de Franciscis V, et al. Signalling of the Ret receptor tyrosine kinase through the c-Jun NH2-terminal protein kinase (JNKS): evidence for a divergence of the ERKs and JNKs pathways induced by RET. Oncogene 1998;16:2435-45.
30. Chang L, Karin M. Mammalian MAP kinase signalling cascades. Science 2001;410:37-40.
31. Xia Z, Dikens M, Raingeaud J, Davis RJ, Greenberg ME. Opposing effects of ERK and JNK-p38 kinases on apoptosis. Science 1995;270:1326-31.
32. Sprecht MC, Barden CB, Fahey TJ 3rd. P44/p42-MAP kinase expression in papillary thyroid carcinomas. Surgery 2001;130:936-40.
33. Shklyaev SS, Namba H, Mitsutake N, Alipov G, Nagayama Y, Maeda S, et al. Transient activation of c-Jun NH2-terminal kinase by growth factors influences survival but not apoptosis of human thyrocytes. Thyroid 2001;11:629-36.
34. Burgering BM, Coffer PJ. Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction. Nature 1995;376:599-602.
35. Franke TF, Kaplan DR, Cantley LC. PI3K: downstream AKTion blocks mitosis. Cell 1997;88:435-7.
36. De Vita G, Berlingieri MT, Visconti R, Castellone MD, Viglietto G, Baldassarre G, et al. Akt/protein kinase B promotes survival and hormone-independent proliferation of thyroid cells in the absence of dedifferentiating and transforming effects. Cancer Res 2000;60:3916-20.
37. Saito J, Kohn AD, Roth RA, Noguchi Y, Tatsumo I, Hirai A, et al. Regulation of FRTL-5 thyroid cell growth by phosphatidylinosito (OH) 3 kinase-dependent Akt-mediated signaling. Thyroid 2001;11:339-51.
38. Ringel MD, Hayre N, Saito J, Saunier B, Schuppert F, Burch H, et al. Overexpression and overactivation of Akt in thyroid carcinoma. Cancer Res 2001;61:6105-11.
39. Miyakawa M, Tsushima T, Murakami H, Wakai K, Isozaki O, Takano K. Increased expression of phosphorylated p70S6 kinase and Akt in papillary thyroid cancer tissues. Endocr J 2003;50:77-83.